Cytomegalovirus Infection

Virus

CMV: dsDNA, Herpesviridae — lifelong LATENCY (same general pattern as HSV/VZV, EBV; distinct latency sites/consequences). Ubiquitous — seroprevalence often 50-90%. Primary infection in immunocompetent adult: usually asymptomatic/mild mono-like. Ubiquity + mild adult disease → much maternal infection goes unnoticed.

Congenital CMV — key epidemiology fact

MOST COMMON CONGENITAL INFECTION OVERALL — more frequent than any single other TORCH infection (high-yield, contrary to historical emphasis on rubella/toxo).

Transmission: PRIMARY maternal infection (higher transmission/severity risk) OR NON-PRIMARY (reactivation of latent CMV, or reinfection with different strain in seropositive mother) — KEY CONTRAST vs rubella: maternal CMV seropositivity does NOT fully protect fetus in subsequent pregnancy (unlike rubella’s more complete immunity protection).

Clinical

~85-90% ASYMPTOMATIC at birth. Of these, up to ~10-15% develop DELAYED SENSORINEURAL HEARING LOSS → CMV = LEADING INFECTIOUS CAUSE of congenital sensorineural hearing loss. Practical implication: asymptomatic-appearing infected infants need LONG-TERM AUDIOLOGICAL FOLLOW-UP.

~10-15% symptomatic at birth: TORCH constellation (hepatosplenomegaly, jaundice, thrombocytopenic purpura/“blueberry muffin” rash — shared w/ rubella) + DISTINCTIVE: PERIVENTRICULAR intracranial calcifications. KEY CONTRAST vs congenital toxoplasmosis: toxo = DIFFUSE calcifications (not periventricular) — frequently tested radiological distinction between these two TORCH infections. Also: microcephaly, chorioretinitis.

Diagnosis

Urine or saliva viral culture/PCR WITHIN FIRST 3 WEEKS OF LIFE = standard for confirming congenital (vs postnatal) infection. KEY TIMING CUTOFF — testing after 3wk can’t reliably distinguish congenital from postnatally-acquired (breast milk, contact) CMV.

Treatment

Ganciclovir or valganciclovir (targets CMV DNA polymerase, distinct from aciclovir-class for HSV/VZV) — used for SYMPTOMATIC congenital CMV, improves hearing/neurodevelopmental outcomes if given neonatally. Contrast vs rubella (no specific antiviral at all). NOT routinely given for asymptomatic congenital CMV (evolving evidence/risk-benefit uncertainty) — audiological surveillance instead.

The Virus — A Genuinely Ubiquitous Herpesvirus

Cytomegalovirus (CMV) is a double-stranded DNA virus of the Herpesviridae family, sharing that family’s genuinely defining biological feature of establishing lifelong latency after primary infection (the same general latency-and-reactivation pattern covered under Herpes Simplex and Varicella-Zoster Virus Infections and Infectious Mononucleosis (Epstein-Barr Virus), though CMV, HSV, VZV, and EBV are genuinely distinct herpesviruses with different specific latency sites and clinical consequences) — CMV is, genuinely, remarkably widespread and ubiquitous, with seroprevalence in adult populations frequently exceeding 50-90% depending on the population studied, and primary infection in an immunocompetent host is typically asymptomatic or produces only a mild, mononucleosis-like illness — this combination of ubiquity and typically mild adult disease is precisely what makes congenital CMV a genuinely important, easily under-recognized public health problem, since so much maternal CMV infection in pregnancy passes essentially unnoticed.

Congenital CMV — The Most Common Congenital Infection

A genuinely, specifically important epidemiological point worth remembering precisely: CMV is the most common congenital infection overall, more frequent than any other single infection covered under the TORCH framework — a real, high-yield fact given how much clinical and public-health emphasis on congenital infection historically centres on rubella and toxoplasmosis despite CMV’s greater actual frequency. Maternal-to-fetal transmission can occur following either primary maternal infection (first-time infection during pregnancy, genuinely, specifically carrying substantially higher transmission and severe-disease risk to the fetus) or, genuinely importantly and a real point of contrast with several other TORCH infections, non-primary infection (reactivation of latent maternal CMV, or reinfection with a different CMV strain in a mother with pre-existing immunity) — this non-primary transmission possibility means, unlike rubella where pre-existing maternal immunity essentially eliminates fetal risk, maternal CMV seropositivity does not fully protect the fetus in a subsequent pregnancy, a genuinely important, specifically testable point of distinction from rubella’s more complete immunity-conferred protection.

Clinical Manifestations

The large majority of congenitally infected infants — genuinely, specifically worth remembering, roughly 85-90% — are asymptomatic at birth, though a substantial proportion of this asymptomatic group (genuinely, importantly, up to around 10-15%) will go on to develop delayed sensorineural hearing loss, making congenital CMV, genuinely and specifically, the leading infectious cause of congenital sensorineural hearing loss — a real, high-yield point worth remembering precisely, and one carrying genuine practical importance since this delayed hearing-loss risk means asymptomatic-appearing CMV-infected infants still warrant long-term audiological follow-up even without any other apparent abnormality at birth. The minority (roughly 10-15%) who are symptomatic at birth present with the broader TORCH constellation described under TORCH Complex and Congenital Infections — hepatosplenomegaly, jaundice, thrombocytopenic purpura (the “blueberry muffin” rash, shared with congenital rubella), and, genuinely distinctively for CMV, periventricular intracranial calcifications on neuroimaging — a genuinely important, specifically testable point of radiological distinction worth holding in deliberate contrast with congenital toxoplasmosis’s characteristically diffuse (rather than periventricular) intracranial calcification pattern, covered under Congenital Toxoplasmosis, since this calcification-distribution distinction is a real, frequently tested point of contrast between these two TORCH infections. Microcephaly and chorioretinitis also occur in symptomatic congenital CMV.

Diagnosis

Urine or saliva viral culture or PCR within the first 3 weeks of life is the standard, definitive diagnostic approach for confirming congenital (as opposed to postnatally-acquired) CMV infection — this genuinely, specifically important 3-week timing cutoff is worth remembering precisely, since testing beyond this window cannot reliably distinguish true congenital infection from CMV acquired postnatally (from breast milk, close contact, or other postnatal exposure), a real, practically important diagnostic-timing principle distinctive to this infection.

Treatment

Ganciclovir or valganciclovir (antiviral agents targeting CMV DNA polymerase, distinct from the aciclovir-class agents used against HSV/VZV) are used specifically in symptomatic congenital CMV disease, genuinely, specifically shown to improve hearing outcomes and neurodevelopmental outcomes when given during the neonatal period — a real, important treatment consideration distinguishing congenital CMV from several other TORCH infections lacking any specific antiviral treatment option (rubella, for instance). Treatment is genuinely not routinely given for asymptomatic congenital CMV, reflecting ongoing clinical uncertainty and evolving evidence regarding the risk-benefit balance of antiviral treatment in this specific, larger asymptomatic population — asymptomatic infants instead receive the audiological surveillance described above rather than antiviral therapy.